31 Aug Fewer Overall New Cardiovascular Drugs, But More Biologics Researched

MedicalResearch.com Interview with:

Dr. Aaron Kesselheim

Aaron S. Kesselheim, M.D., J.D., M.P.H.
Associate Professor of Medicine at Harvard Medical School
Director, Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women’s Hospital
Boston MA 02120

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: It has been previously reported that the number of new cardiovascular drugs approved by the U.S. Food and Drug Administration (FDA) has declined in recent years. So we sought to empirically assess trends in the development of new cardiovascular therapeutics.

MedicalResearch.com: What should readers take away from your report?

Response: While the overall number of new investigational cardiovascular drugs has declined, we also found a relative growth in the number of drugs targeting novel biological pathways, suggesting that the observed contraction in cardiovascular research output may be driven by fewer follow-on drugs.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: Policymakers should assess how to best support research aimed at improving gaps in the understanding of the pathophysiological bases for cardiovascular disorders, as well as facilitating translational efforts to develop new cardiovascular therapeutics.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

[wysija_form id=”5″]

Last Updated on August 31, 2016 by Marie Benz MD FAAD